Astellas Pharma

From SourceWatch
Jump to: navigation, search

In October 2009, Medivation announced a global agreement with Astellas Pharma Inc. to develop and commercialize enzalutamide (formerly MDV3100). [1]

Resources and articles

Related Sourcewatch

References